Use of Interferon-α for Prevention of Hepatocellular Carcinoma in Patients with Chronic Active Hepatitis C with Cirrhosis

  • S. Nishiguchi
  • S. Nakatani
  • A. Tamori
  • T. Takeda
  • S. Shiomi
  • S. Seki
  • T. Kuroki
Conference paper


Hepatitis C virus (HCV) is a more important factor associated with hepatocellular carcinoma than hepatitis B virus (HBV) in Japan and certain Western countries [1–3]. Some patients who contracted chronic non-A, non-B hepatitis after blood transfusion and hepatocellular carcinoma many years later have been studied in detail [4–6]. These studies proved that patients with chronic HCV infection often develop hepatocellular carcinoma [7]. The cumulative incidence of hepatocellular carcinoma in patients who had blood transfusions and were negative for hepatitis B surface antigen (HBsAg) was 53% (13/26) during 6 years of observation [8]. All of these patients had HCV antibodies. The mechanism by which hepatocellular carcinoma develops in the presence of HCV is unknown.


Hepatocellular Carcinoma Serum Albumin Level Chronic Active Hepatitis Histological Activity Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bruix J, Barrera JM, Calvet X, et al (1989) Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet ii:1004–1006CrossRefGoogle Scholar
  2. 2.
    Colombo M, Kuo G, Choo QL, et al (1989) Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet ii: 1006–1008CrossRefGoogle Scholar
  3. 3.
    Nishioka K, Watanabe J, Furuta S, et al (1991) A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 67:429–433PubMedCrossRefGoogle Scholar
  4. 4.
    Resnick RH, Stone K, Antonioli D (1983) Primary hepatocellular carcinoma following non-A, non-B posttransfusion hepatitis. Dig Dis Sci 28:908–911PubMedCrossRefGoogle Scholar
  5. 5.
    Kiyosawa K, Akahane Y, Nagata A, Furuta S (1984) Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis. Am J Gastroenterol 79:777–781PubMedGoogle Scholar
  6. 6.
    Gilliam JH II, Geisinger KR, Richter JE (1984) Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis. Ann Intern Med 101:794–795PubMedGoogle Scholar
  7. 7.
    Tremolada F, Benvegnu L, Casarin C, Pontisso P, Tagger A Alberti A (1990) Antibody to hepatitis C virus in hepatocellular carcinoma. Lancet 335:300–301CrossRefGoogle Scholar
  8. 8.
    Oka H, Kurioka N, Kim K, et al (1990) Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 12:680–687PubMedCrossRefGoogle Scholar
  9. 9.
    Hoofnagle JH, Mullen KD, Jones DB, et al (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 315:1575–1578PubMedCrossRefGoogle Scholar
  10. 10.
    Di Bisceglie AM, Martin P, Kassianides C, et al (1989) Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind placebo-controlled trial. N Engl J Med 321:1506–1510PubMedCrossRefGoogle Scholar
  11. 11.
    Shindo M, Di Bisceglie AM, Hoofnagle JH (1992) Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology 15:1013–1016PubMedCrossRefGoogle Scholar
  12. 12.
    Kiyosawa K, Sodeyama T, Tanaka E, et al (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12:671–675PubMedCrossRefGoogle Scholar
  13. 13.
    Knodell RG, Ishak KG, Black WC, et al (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435PubMedCrossRefGoogle Scholar
  14. 14.
    Pugh RNH, Murray-Lyon IM, Dawson JL, et al (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649PubMedCrossRefGoogle Scholar
  15. 15.
    Sherlock S, Dooley J (1997) Diseases of the liver and biliary system, 9th edn. Blackwell, Oxford, p 367Google Scholar
  16. 16.
    Hill AB (1963) Medical ethics and controlled trials. Br Med J i:1043–1049CrossRefGoogle Scholar
  17. 17.
    Nishiguchi S, Kuroki T, Ueda T, et al (1992) Detection of hepatitis C virus antibody in the absence of viral RNA in patients with autoimmune hepatitis. Ann Intern Med 116:21–25PubMedGoogle Scholar
  18. 18.
    Okamoto H, Tokita H, Sakamoto M, et al (1993) Characterization of the genomic sequence of type V (or 3a) hepatic C virus isolates and PCR primers for specific detection. J Gen Virol 74:2835–2890Google Scholar
  19. 19.
    Nishiguchi S, Kuroki T, Nakatani S, et al (1995) Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051–1056PubMedCrossRefGoogle Scholar
  20. 20.
    Mazzella G, Accogli E, Sottili S, et al (1996) Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24:141–147PubMedCrossRefGoogle Scholar
  21. 21.
    Fattovich G, Giustina G, Degos F, et al (1997) Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 27:201–205PubMedCrossRefGoogle Scholar
  22. 22.
    Chisari FV, Klopchin K, Moriyama T, et al (1989) Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59:1145–1156PubMedCrossRefGoogle Scholar
  23. 23.
    Vogelstein B, Fearon ER, Hamilton SR, et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532PubMedCrossRefGoogle Scholar
  24. 24.
    Okuda K (1992) Hepatocellular carcinoma: recent progress. Hepatology 15:948–963PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1999

Authors and Affiliations

  • S. Nishiguchi
    • 1
  • S. Nakatani
    • 1
  • A. Tamori
    • 1
  • T. Takeda
    • 1
  • S. Shiomi
    • 1
  • S. Seki
    • 1
  • T. Kuroki
    • 1
  1. 1.Third Department of Internal MedicineOsaka City University Medical SchoolAbeno-ku, OsakaJapan

Personalised recommendations